Research and development of protelytics from natural sources for the treatment of thrombotic states and chronic wounds (Q11201): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in 1 language: remove_english_label) |
(Changed label, description and/or aliases in 1 language: translated_label) |
||
| label / en | label / en | ||
Research and development of protelytics from natural sources for the treatment of thrombotic states and chronic wounds | |||
Revision as of 06:33, 22 October 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Research and development of protelytics from natural sources for the treatment of thrombotic states and chronic wounds |
Project in Czech Republic financed by DG Regio |
Statements
5,769,000.0 Czech koruna
0 references
15,384,000.0 Czech koruna
0 references
37.5 percent
0 references
12 May 2017
0 references
17 April 2020
0 references
VUAB Pharma a.s.
0 references
50°9'46.91"N, 14°23'2.26"E
0 references
25263
0 references
Předmětem projektu je vývoj postupu přípravy vysoce účinných proteolytik (KR-X) z antarktického krillu, které budou použity v různých oborech medicíny. Výstupem, kromě technologických postupů přípravy, budou dva prototypy proteolytika KR-X - pro léčbu chronických ran a pro trombolýzu cévních trombů. Díky mechanismu působení enzymu na nežádoucí fibrin a fragmenty se předpokládá u pacientů lepší snášenlivost a nižší bolestivost léčby oproti agresívnějším enzymatickým prostředkům. a. (Czech)
0 references
The project concerns the development of a procedure for the preparation of highly effective proteolytics (KR-X) from Antarctic Krill, which will be used in the various fields of medicine. In addition to the preparation process, there will be two protypes Proteolytics KR-X — for the treatment of chronic wounds and for the thrombolysis of vascular thrombosis (KR-X). The mechanism of action of the enzyme on unwanted fibrin and fragments is expected to improve the degree of tolerance and pain of treatment in patients than the aggressive enzymatic means of treatment. (English)
0 references
Identifiers
CZ.01.1.02/0.0/0.0/16_083/0010108
0 references